Core Viewpoint - The stock of药捷安康-B (02617) experienced a significant decline of over 11% during trading, with a current drop of 9.74% to HKD 176.2, and a trading volume of HKD 591 million. The company announced plans to convert 44.9711 million domestic shares held by 10 shareholders into H-shares, representing approximately 11.33% of the total issued shares, pending regulatory approvals [1][1][1]. Group 1 - The company’s stock price fell sharply after a recent surge, indicating volatility in investor sentiment [1][1]. - The recent rebound from October 16 to 17 saw a cumulative increase of nearly 80%, driven by international short-term speculative funds [1][1]. - The rebound was characterized as a "window for unloading" by domestic major funds, suggesting that the primary holders were selling rather than buying [1][1]. Group 2 - The analysis from智通财经APP highlighted that the recent price surge was not supported by the main holding group, which instead became the largest sellers [1][1]. - The sustainability of the rebound is questioned, as it relies heavily on subsequent market participation and inflow of speculative funds [1][1].
药捷安康-B盘中跌超11% 公司拟H股全流通 占已发行股份总数约11.33%